Nurix Therapeutics, Inc. $NRIX Shares Sold by Commodore Capital LP

Commodore Capital LP reduced its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 39.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,275,000 shares of the company’s stock after selling 1,505,055 shares during the period. Nurix Therapeutics makes up 2.9% of Commodore Capital LP’s investment portfolio, making the stock its 16th largest position. Commodore Capital LP’s holdings in Nurix Therapeutics were worth $43,157,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in shares of Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after buying an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in Nurix Therapeutics during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in Nurix Therapeutics during the 4th quarter worth $33,000. Wexford Capital LP purchased a new stake in Nurix Therapeutics in the third quarter valued at $41,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Nurix Therapeutics by 66.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock valued at $93,000 after acquiring an additional 1,970 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NRIX shares. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Tuesday, April 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a research report on Monday. Truist Financial increased their price objective on Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, June 8th. Finally, Jefferies Financial Group raised their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $17.12 on Thursday. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -5.42 and a beta of 1.86. The firm’s fifty day moving average price is $16.51 and its 200 day moving average price is $16.91. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The firm had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. As a group, analysts expect that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current fiscal year.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,214 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the transaction, the insider owned 120,399 shares in the company, valued at approximately $2,004,643.35. The trade was a 2.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 19,657 shares of company stock valued at $326,586 over the last three months. 6.70% of the stock is currently owned by corporate insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.